Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Stage IV Thyroid Gland Medullary Carcinoma AJCC v8”

9 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 9 results

Early research (Phase 1)Active Not RecruitingNCT04514484
What this trial is testing

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Who this might be right for
Advanced Differentiated Thyroid Gland CarcinomaAdvanced Head and Neck CarcinomaAdvanced Hepatocellular Carcinoma+60 more
National Cancer Institute (NCI) 8
Not applicableLooking for participantsNCT04216732
What this trial is testing

Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management

Who this might be right for
Advanced Thyroid Gland Medullary CarcinomaStage III Thyroid Gland Medullary Carcinoma AJCC v8Stage IV Thyroid Gland Medullary Carcinoma AJCC v8+3 more
M.D. Anderson Cancer Center 2,030
Testing effectiveness (Phase 2)WithdrawnNCT04106843
What this trial is testing

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Who this might be right for
Locally Advanced Adrenal Gland PheochromocytomaLocally Advanced ParagangliomaMetastatic Adrenal Gland Pheochromocytoma+11 more
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT03866382
What this trial is testing

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Who this might be right for
Bladder AdenocarcinomaBladder Clear Cell AdenocarcinomaBladder Mixed Adenocarcinoma+42 more
National Cancer Institute (NCI) 314
Testing effectiveness (Phase 2)Active Not RecruitingNCT04071223
What this trial is testing

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

Who this might be right for
Advanced Renal Cell CarcinomaChromophobe Renal Cell CarcinomaClear Cell Renal Cell Carcinoma+6 more
National Cancer Institute (NCI) 134
Testing effectiveness (Phase 2)Ended earlyNCT03274258
What this trial is testing

Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma

Who this might be right for
Kidney Medullary CarcinomaLoss of INI 1 Protein ExpressionStage III Renal Cell Cancer AJCC v8+1 more
M.D. Anderson Cancer Center 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT03587662
What this trial is testing

Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Who this might be right for
Metastatic Kidney Medullary CarcinomaMetastatic Renal Cell CarcinomaSMARCB1 Negative+2 more
M.D. Anderson Cancer Center 30
Not applicableActive Not RecruitingNCT04467021
What this trial is testing

Cancer and Blood Pressure Management, CARISMA Study

Who this might be right for
Cardiovascular DisorderChronic Kidney DiseaseMetastatic Renal Cell Carcinoma+6 more
ECOG-ACRIN Cancer Research Group 61
Early research (Phase 1)Active Not RecruitingNCT02496208
What this trial is testing

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

Who this might be right for
Bladder Small Cell Neuroendocrine CarcinomaBladder Squamous Cell CarcinomaBladder Urothelial Carcinoma+27 more
National Cancer Institute (NCI) 152